Browsing Tag
Ovarian Cancer
26 posts
NeoGenomics launches PanTracer Tissue and HRD-enhanced profiling to accelerate ovarian cancer treatment decisions
NeoGenomics launches PanTracer Tissue and PanTracer Tissue + HRD to fast-track ovarian cancer treatment with next-gen genomic profiling and rapid HRD testing.
Cleo Diagnostics (ASX:COV) gains PLCO biobank access to strengthen FDA submission for ovarian cancer test
Cleo Diagnostics secures PLCO biobank access to enhance its ovarian cancer test FDA filing. Find out how this milestone strengthens global regulatory strategy.
AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant…
New data from Incyte highlights efficacy of CDK2 inhibitor in ovarian cancer; Pivotal trials expected in 2025
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing…
BiVictriX Therapeutics secures Innovate UK grant to advance ovarian cancer treatment
BiVictriX Therapeutics plc (AIM: BVX), a pioneering drug discovery and development company, has announced receiving a substantial grant…
LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership…
Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the…
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 “ELUCIDATE” study, marking the first trial…
ImmunoGen secures up to $175m from Pharmakon Advisors to accelerate oncology growth
ImmunoGen secures up to $175M in non-dilutive funding from Pharmakon to fuel Elahere’s launch and expand its next-gen ADC pipeline. Read the full breakdown.
TCR2 Therapeutics reports positive interim results for gavo-cel in early-stage solid tumors trial
TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial…